MedTrace Logo

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

NCT01221519 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-01-19

No results posted yet for this study

Summary

The purpose of this study is to assess the relative bioavailability by measuring the extent and rate of absorption of different tablet formulations of AZD1656 in T2DM patients.

Conditions

Interventions

DRUG

AZD1656

3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake

Sponsors & Collaborators

Principal Investigators

  • Eva Johnsson, MD, PhD · AstraZeneca Sweden

  • Mark Matson, MD · Prism Research

  • Mirjana Kujacic Kujacic, MD, PhD · AstraZeneca R&D Mölndal

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01221519 on ClinicalTrials.gov